These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11554590)

  • 1. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.
    Larson PJ; High KA
    Adv Exp Med Biol; 2001; 489():45-57. PubMed ID: 11554590
    [No Abstract]   [Full Text] [Related]  

  • 2. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for hemophilia.
    Lynch CM
    Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
    Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B
    Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle as a target for supplementary factor IX gene transfer.
    Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
    Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
    Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
    Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.
    Buchlis G; Podsakoff GM; Radu A; Hawk SM; Flake AW; Mingozzi F; High KA
    Blood; 2012 Mar; 119(13):3038-41. PubMed ID: 22271447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
    Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
    Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.
    Arruda VR; Fields PA; Milner R; Wainwright L; De Miguel MP; Donovan PJ; Herzog RW; Nichols TC; Biegel JA; Razavi M; Dake M; Huff D; Flake AW; Couto L; Kay MA; High KA
    Mol Ther; 2001 Dec; 4(6):586-92. PubMed ID: 11735343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
    Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
    Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Portal vein delivery of viral vectors for gene therapy for hemophilia.
    Sherman A; Schlachterman A; Cooper M; Merricks EP; Raymer RA; Bellinger DA; Herzog RW; Nichols TC
    Methods Mol Biol; 2014; 1114():413-26. PubMed ID: 24557919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.